U.S. Water Utilities Stock News

What the latest earnings and Spectrum moves mean for Charter Communications (CHTR) Charter Communications (CHTR) has drawn fresh attention after reporting fourth quarter and full year 2025 results that showed lower sales and net income, along with continued internet customer losses at Spectrum, as well as new Wi-Fi offerings and service guarantees. See our latest analysis for Charter Communications. The recent earnings update, continued Spectrum internet customer losses and ongoing share...

CACI International (CACI) is back in focus after securing a five year US$250 million task order with the US Army to support electronic warfare and spectrum dominance capabilities, extending its role in defense technology programs. See our latest analysis for CACI International. At a share price of US$598.32, CACI’s recent 6.95% 1 month share price return and 59.45% 1 year total shareholder return indicate that momentum has been building. The new US Army task order adds to a series of contract...

Helmerich & Payne (HP) opened Q1 2026 with revenue of about US$1.0 billion and a basic EPS loss of US$0.97, as net income excluding extra items came in at a loss of US$96.7 million. Over the last year, the company has seen quarterly revenue stay around the US$1.0 billion mark while EPS has swung from a profit of US$0.55 in Q1 2025 to losses of US$1.64 in Q3 2025, US$0.58 in Q4 2025, and now US$0.97 in Q1 2026. This sets up a results season in which investors are likely to focus on how quickly...

Selective Insurance Group director increased a personal stake in the company through a recent share purchase. The transaction coincides with board approved amendments to the company’s bylaws on director eligibility and leadership responsibilities. The combination of insider buying and governance updates is drawing attention from existing shareholders and potential investors. Selective Insurance Group, traded as NasdaqGS:SIGI, is drawing fresh interest after this insider move at a share...

Black Hills reported fourth quarter FY 2025 revenue of US$635.5 million with basic EPS of US$1.39, alongside trailing twelve month revenue of US$2.3 billion and EPS of US$3.99 that reflects steady earnings over the past year. The company has seen revenue move from US$2.1 billion and EPS of US$3.70 on a trailing basis in Q3 FY 2024 to US$2.3 billion and EPS of US$3.99 by Q4 FY 2025. This sets up a story where the key question is how much of that earnings power is repeatable. With a trailing...

O'Reilly Automotive (ORLY) has wrapped up FY 2025 with fourth quarter revenue of US$4.4b and basic EPS of US$0.72, alongside trailing 12 month revenue of US$17.8b and EPS of US$2.98 that frame the latest print in a broader context. Over recent quarters, the company has seen revenue range from US$4.1b to US$4.7b and quarterly EPS move between US$0.63 and US$0.86, giving investors a clear view of how sales and earnings have tracked through the year. With net income, EPS and margins all firmly...

Why Camping World Holdings (CWH) Is Back on Investors’ Radar With no single headline event driving attention to Camping World Holdings (CWH) today, recent trading performance and fundamentals are giving investors fresh reasons to reassess the RV retailer’s risk and return profile. See our latest analysis for Camping World Holdings. Camping World’s recent trading has been choppy, with a 1 day share price return of 4.54% and a 7 day share price return of 2.18%. Meanwhile, a 30 day share price...

Veralto (VLTO) has wrapped up FY 2025 with fourth quarter revenue of US$1,396 million and basic EPS of US$1.02, capping a year in which trailing twelve month revenue reached US$5.5 billion and EPS came in at US$3.79, alongside reported earnings growth of 12.8% over the past year. Over the last six reported quarters, the company has seen revenue move from US$1,314 million in Q3 2024 to US$1,396 million in Q4 2025. Quarterly EPS ranged between US$0.89 and US$1.02 across that period, giving...

If you are wondering whether DigitalOcean Holdings is priced attractively today, this article walks through the numbers behind the stock rather than relying on headlines or hype. The shares recently closed at US$57.66, with returns of 2.7% over the last 7 days, 6.8% over 30 days, 17.7% year to date, and 31.1% over the past year. This gives useful context before comparing that price to underlying value. Recent coverage of DigitalOcean has focused on its position as a cloud platform for...

Lumen Technologies (LUMN) FY 2025 earnings snapshot Lumen Technologies (LUMN) closed FY 2025 with fourth quarter revenue of US$3.0 billion and basic EPS of roughly US$0.00, as net income excluding extra items landed at a loss of US$2 million. The company has seen quarterly revenue move from US$3.3 billion and basic EPS of US$0.09 in Q4 2024 to US$3.0 billion and a near breakeven basic EPS in Q4 2025, alongside a trailing twelve month loss of US$1.7 billion on basic EPS of US$1.75. With...

If you are wondering whether Parker-Hannifin shares around US$967.62 still offer value after a strong run, you are not alone. That is exactly what this article will unpack for you. The stock has returned 2.0% over the last 7 days, 4.2% over 30 days, 8.2% year to date, 41.3% over 1 year, 184.3% over 3 years and 277.7% over 5 years, which naturally raises questions about how much of the story is already reflected in the price. Recent attention on Parker-Hannifin has centered on its position in...

Why U.S. Physical Therapy Is Drawing Fresh Attention U.S. Physical Therapy (USPH) is back on investor radars after a recent share price move, with the stock up around 3% over the past month and roughly 14% in the past 3 months. See our latest analysis for U.S. Physical Therapy. That recent 3 month share price return of 13.81% sits against a one year total shareholder return decline of 1.89% and a 5 year total shareholder return decline of 33.30%, which suggests near term momentum has picked...

Polaryx Therapeutics (PLYX) has drawn investor attention after a sharp 28.9% single day share price decline, with the stock closing at US$16. This move comes against a year to date return of negative 54.3%. See our latest analysis for Polaryx Therapeutics. The sharp 28.9% single day share price return decline and the year to date share price return of 54.3% point to fading momentum, suggesting that recent moves reflect shifting risk perception more than steady longer term sentiment. If...

Park Hotels & Resorts recently drew attention as major brokerages issued mixed ratings ahead of its upcoming Q4 and full-year 2025 results, while the company continued reshaping its portfolio and refinancing debt maturities with US$2.00 billion in credit facilities. This flurry of analyst views, combined with Park’s shift toward higher-quality domestic assets and efforts to address near-term debt, highlights how governance, balance sheet management, and asset quality are becoming central to...

AtriCure (ATRC) has drawn investor attention after a period of mixed share performance, with a loss of 9.18% over the past month but a 16.83% gain in the past 3 months. See our latest analysis for AtriCure. At a share price of $36.80, AtriCure’s recent 7 day and 1 month share price returns of 2.57% and 9.18% declines contrast with a 16.83% gain over 90 days. The 1 year, 3 year and 5 year total shareholder returns of 10.96%, 13.92% and 41.49% declines indicate that momentum has only recently...

If you are trying to figure out whether Waystar Holding stock now offers value, it helps to step back from the recent share price swings and look at what the current market price might be implying. Over the recent period, the shares closed at US$23.99, with returns of a 13.1% decline over 7 days, a 24.5% decline over 30 days, a 23.5% decline year to date, and a 42.8% decline over 1 year, which may prompt questions about how risk and potential reward are being priced in. These moves sit...

Truist Financial (NYSE:TFC) has launched an AI powered integrated receivables platform for commercial and corporate clients. The new platform uses machine learning tools to support cash management, operational efficiency, and fraud controls. The offering targets long standing receivables and payments pain points for finance teams across Truist’s business client base. For investors watching Truist Financial at a share price of $55.14, this move sits alongside a period of positive stock...

Quaker Chemical (KWR) drew fresh attention after its recent earnings modestly topped expectations, with management pointing to strong customer demand, realized synergies, and greater use of higher-value formulations as key drivers. See our latest analysis for Quaker Chemical. The recent earnings beat has been followed by strong momentum in the share price, with a 1-month share price return of 20.28% and a 90-day share price return of 29.22%. The 1-year total shareholder return of 26.60%...

Darden Restaurants (NYSE:DRI) is discontinuing the Bahama Breeze brand and closing 14 locations. Roughly half of the remaining Bahama Breeze sites will be converted to other Darden concepts. The move is part of a broader portfolio reshaping focused on brands with stronger unit economics. Darden Restaurants, trading at $212.22, is acting on a full review of its brand portfolio by winding down Bahama Breeze and reallocating those locations to concepts it views as more scalable. The stock has...

Weatherford International’s FY 2025 Earnings Snapshot Weatherford International (WFRD) closed out FY 2025 with Q4 revenue of US$1.3b and basic EPS of US$1.92, backed by net income of US$138m. The company has seen quarterly revenue range from US$1,193m to US$1,341m across the last six reported periods, while basic EPS has moved between US$1.04 and US$2.14 over the same stretch. This provides a clear view of how the top and bottom lines have tracked through the cycle. With a trailing twelve...

In January 2026, Cogent Biosciences announced that the FDA granted Breakthrough Therapy Designation to bezuclastinib plus sunitinib for previously imatinib-treated GIST, based on PEAK trial data showing improved progression-free survival and a favorable safety profile compared with sunitinib alone. The FDA’s decision to review Cogent’s New Drug Application under its Real-Time Oncology Review program highlights regulatory interest in potentially accelerating access to this combination...

Graco (GGG) is back in focus after its fourth quarter and full year 2025 earnings, where sales, net income, and earnings per share all came in higher than the prior year’s levels. See our latest analysis for Graco. The earnings release and 2026 sales guidance have come alongside a 1-day share price return of 3.14%, adding to a 30-day share price return of 9.66% and a 1-year total shareholder return of 9.69%. Taken together, these figures suggest that momentum has been picking up recently. If...

Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership. See our latest analysis for Sangamo Therapeutics. Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...

Warby Parker recently highlighted its resilience in a softer consumer backdrop, supported by a broader in-network insurance footprint that now includes Versant and helps capture demand as customers use their vision benefits, particularly in the seasonally important fourth quarter. At the same time, the company is positioning itself as an early mover in intelligent eyewear through partnerships with Google and Samsung, backed by substantial capital and product development support from these...